Web Watch
Figures converted from JPY at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Web Watch in One Page
At $41.83 the equity has absorbed roughly three-quarters of the bull sum-of-the-parts target on a +150% twelve-month rally, but the entire 5-to-10-year thesis collapses onto a small number of observable signals. These five watches track the variables that actually decide the underwriting — reclaim segment margin durability, capacity-execution credibility, the competitive moat under attack, the borrowed regulatory ringfence shielding GRITEK, and capital allocation discipline under a founder who controls 79.6% of the votes and has retired three mid-term plans in three years on the non-reclaim side.
The set is deliberately weighted toward evidence that would change the long-term view rather than evidence that anticipates the next quarterly print. The single near-term hard date — Q2 FY12/26 results on 7 August 2026 — sits inside watch #1; everything else either feeds, contextualizes, or counterweighs the reclaim-margin verdict. Cadences are tighter (1d) where the signal is event-driven and time-sensitive, and looser (1w) where the relevant disclosures are slow-moving governance, plan refreshes, or capital-return announcements.
Active Monitors
| Rank | Watch item | Cadence | Why it matters | What would be detected |
|---|---|---|---|---|
| 1 | Reclaim segment operating margin trajectory | Daily | Reclaim is 36% of revenue but 71% of segment operating income at 36.9% margin — the single piece of evidence underwriting the equity. The 9-year band (35.1%–40.6%) has already compressed 370 bps from peak, and the published moat-breaker (sub-35% for two consecutive quarters) sits ~200 bps below the FY2025 print. | Q2 FY26 (7 Aug 2026) and Q3 FY26 segment-table prints; LTA-renewal references with TSMC / Samsung / SK Hynix / Intel; utilization commentary at Sanbongi and Tainan; any change to the FY2026 $529M / $97M guide. |
| 2 | Sanbongi Plant 7 commissioning and reclaim capacity execution | Daily | Pull-forward of Sanbongi Plant 7 to FY2026 (from FY2027) is the moat showing up as visible, contracted demand — but only if the plant commissions on schedule at ≥85% utilization. A slip or sub-70% fill rate would refute the moat-broadening narrative and re-escalate capex/depreciation. | Mass-production start dates; permit and land-use approvals at the Inner Mongolia plant (announced 19 Mar 2026); LTA-volume disclosures in supplementary materials; Tainan Plant 2 ramp progress; any capex over-run signal inside the $255M FY26–28 envelope. |
| 3 | Ferrotec and Chinese state-backed reclaim entrants | Daily | The combination failure mode — reclaim margin below 35% concurrent with a Big Fund III reclaim disbursement — collapses both the moat and the prime-segment optionality in the same window. Ferrotec is the only listed peer with mix close enough to RST to matter and is publicly adding reclaim-adjacent capacity in three Chinese sites. | Ferrotec capex announcements in Changshan, Yinchuan or Sichuan; Ferrotec semi-equipment segment margin reads (already 18.2% → 12.5% YoY); Big Fund III disbursements toward Chinese reclaim greenfields; new reclaim qualifications at Mimasu, Kinik, or Phoenix Silicon; any named customer multi-sourcing disclosure. |
| 4 | US BIS export controls, GRITEK STAR Market disclosures, and SGRS 12-inch trajectory | Daily | The prime segment's economics rest on a policy environment, not company-specific capability. SGRS has already rephased from 150K wafers/month 2026 to 50K wafers/month 2027 citing "Japan-China relations"; $139–277M of GRITEK capex is still to be drawn; FY25 included $13M of Chinese subsidies (vs $7M FY24) with the CEO flagging part as a "past-period catch-up." | BIS rule windows on mature-node wafer materials; GRITEK (688521.SH) quarterly 8-inch ASP and subsidy income; SGRS milestone slips; Beijing subsidy resets; Japan-China policy moves affecting GRINM SEMICONDUCTOR MATERIALS. |
| 5 | Capital allocation, buyback signal, and the Feb 2027 mid-term plan refresh | Weekly | Three plans retired in three years on the non-reclaim side. A third consecutive walk-back of the FY2028 $725M / $120M target would collapse adjacency credibility and put roughly 17–23% of market cap at risk. Capital return is the only un-tested element of the founder-alignment story — $485M net cash, never a buyback, founder owns 79.6% of votes. | First material share-buyback authorization; DPS revisions above the $0.35 FY2026 guide; the Feb 2027 plan refresh language on FY2028 targets; new M&A with bargain-purchase accounting; capital injections into Chinese subsidiaries via the R.S. Tech Hong Kong vehicle; GRITEK take-private proposals; CEO succession disclosures. |
Why These Five
The report converges on five open questions that span five-to-ten years rather than five quarters, and the watch list mirrors them in order of weight:
- Will the reclaim moat hold under Sanbongi 7 ramp dilution? This is the metric the entire equity sits on; if margin holds 36–38% the model re-segments toward quality-materials multiples, if it slips below 35% structurally the appropriate multiple resets to mid-single-digit EV/EBITDA.
- Is the capacity build-out customer-driven? A clean Sanbongi 7 commissioning at high utilization converts the pull-forward into operational proof. A slip refutes the moat-broadening claim.
- Is the moat actually being attacked, or is the threat narrative academic? Ferrotec capex pace and any Big Fund III disbursement decide whether the 35–40% margin band is structural or temporary.
- Does the borrowed ringfence on prime survive the next BIS cycle? SGRS 12-inch has already slipped twice; a third slip combined with a new mature-node rule collapses $139–277M of remaining GRITEK capex into a stranded-asset risk.
- Will the next mid-term plan and capital-return cycle confirm or refute the adjacency-credibility discount the variant view applies? The Feb 2027 plan, a first buyback, and any related-party transaction through the founder's HK vehicle are the discrete tests that resolve the adjacency-premium debate the +150% rally has not yet absorbed.
The watch list is intentionally light on calendar-driven catalysts (sell-side initiations, AGM cycle, sector data points like SEMI MSI) because those tend to inform without resolving. Each of the five above is structured so that a single disclosure can change the underwriting view — either confirming the bull SOTP toward $59.85, validating the bear's $26.46 downside, or holding the verdict in the current watchlist posture until the Q2 FY26 segment table prints.